Article Text

Download PDFPDF
New approach in prophylactic treatment of a challenged HAE patient
  1. Oda Jordal1 and
  2. Anette Bygum2
  1. 1 University of Southern Denmark, Odense, Denmark
  2. 2 Department of Dermatology and Allergy Center, University Hospital of Odense, Odense, Denmark
  1. Correspondence to Oda Jordal, oda.jordal{at}


Hereditary angioedema (HAE) is a relapsing swelling disorder which can cause severe pain, affect quality of life and potentially be life threatening with involvement of the airways. We present a 34-year-old immigrant who suffered from very frequent and severe HAE attacks. The attacks often involved the face, mouth and the airways. She often went to the hospital for treatment, where the language barrier made the situation complicated. The traditional therapy for HAE was not successful treating this patient. In June 2017, off-label treatment with prophylactic subcutaneous complement C1-inhibitor concentrate was initiated. The treatment was very successful and the patient has not been hospitalised since. Treatment for HAE is nowadays under investigation, and many drugs are under development. Especially, medication which works prophylactically and is administered orally or subcutaneously is in the horizon.

  • dermatology
  • genetics
  • medical management
  • immunology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors OJ has primarily written the article, while AB has been the supervisor and the doctor who is responsible for diagnosing and treating the patient.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Anette Bygum has been involved in research and teaching activities with CSL Behring, Shire and Biocryst.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.